Thierry Wurch
Nia Emami
Michael Kalos
Michael Kalos is a graduate of the University of Minnesota Medical School, where he received his PhD from the department of Microbiology with an emphasis in Genetics. He completed postdoctoral fellowships at the Fred Hutchinson Cancer Research Center where he played an early role in the development of genetic approaches to redirect lymphocyte specificity.
In 1997 Dr. Kalos joined Corixa Corporation, where he engaged in the pre-clinical immunological evaluation of novel cancer vaccines for prostate and lung cancer.
In 2004 Dr. Kalos was recruited to City of Hope where he established a GLP-level laboratory focused on the development of biomarker strategies to evaluate T cell immunotherapies.
In 2008 Dr Kalos was recruited to the University of Pennsylvania School of Medicine where he established the Translational and Correlative Studies Laboratory, focused on development and implementation of an integrated biomarker infrastructure as part of the institution's T cell immunotherapy program. Data from his laboratory played an instrumental role in the clinical evaluation and development of the CTL019 program, and has led to a series of high-impact and field-leading publications.
In October 2013 Dr Kalos joined Eli Lilly and company as Chief Scientific Officer for Cancer Immunobiology. At Eli Lilly Dr. Kalos was responsible for establishing and developing a robust and product focused immunotherapy strategy and program.
In March of 2018 Dr. Kalos joined Janssen as Vice President, Immuno-oncology and Oncology Cellular Therapies, where is responsible for developing and leading an integrated Immunotherapy program focused on next-generation and transformative immune therapies.
Dr. Kalos is an internationally recognized expert in T cell immunotherapy.
Marleen van Loenen
Marleen van Loenen is Director Preclinical Development at Gadeta, a R&D company that focusses on the development of αβT cells modified with γδ T cell receptors to combat both hematological and solid cancers. Her experience in and enthusiasm for adoptive immunotherapy strategies started with her PhD at Leiden University Medical Center in TCR-gene transfer for hematological malignancies. Subsequently, she moved to Sanquin Amsterdam to study presence and fitness of tumor-reactive TILs within NSCLC, before joining Gadeta in 2017.
Michael Hudecek
Kip Cross
John Bridgeman
Fiona Thistlethwaite
Dan Ollendorf
